Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor Therapy
- 23 August 2010
- journal article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 8 (12), 1048-1055
- https://doi.org/10.1016/j.cgh.2010.07.022
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2009
- Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 casesJournal of Dermatological Treatment, 2009
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled TrialsClinical Gastroenterology and Hepatology, 2008
- Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel DiseaseGastroenterology, 2008
- Maintenance Therapy with Certolizumab Pegol for Crohn's DiseaseNew England Journal of Medicine, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II studyAlimentary Pharmacology & Therapeutics, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002